Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high116.95 24/03/16
52 week low63.83 21/03/17
52 week change -50.50 (-43.35%)
4 week volume232,613 24/02/17

Media for (AVCT)

Presenter: Dr. Alastair Smith
31/07/2014
Presenter: Dr. Alastair Smith
06/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Avacta CEO to present at UK Investor Show

Avacta Group chief executive Alastair Smith will be presenting at the UK Investor Show at the QE2 Centre, Westminster, ...

Avacta to present at the UK Investor Show

RNS Number: 1169A Avacta Group PLC 22 March 2017 22 nd March 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to present at the UK Investor Show Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the...

Hardman Research: Low response would be positive!

RNS Number: 0035A Avacta Group PLC 21 March 2017 Hardman Research: Low response would be positive! Low response would be positive!: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominat...

Director/PDMR Shareholding

RNS Number: 3868V Avacta Group PLC 30 January 2017 30 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director/PDMR Shareholding Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces the following changes to the equity incentives of its Chief Executive Officer, Alastair Sm...

Result of Annual General Meeting

RNS Number: 7412U Avacta Group PLC 20 January 2017 20 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Result of Annual General Meeting Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier today, all resolutions were duly pas...

Avacta sees substantial progress

Avacta Group has made substantial progress in the past year in demonstrating the performance and differentiation of its ...

Trading Update

RNS Number: 6699U Avacta Group PLC 20 January 2017 20 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") AGM business update and notice of results Substantial progress in therapeutic programme Multiple third party technology evaluations ongoing Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and resea...

Avacta CEO to present at London forum

Avacta Group chief executive Alastair Smith will be presenting at the London Growth and Innovation Forum on 31 Janua...

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Equity Research (AVCT)

hardman & co
Avacta Group Plc
02/11/2016
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
17/10/2016
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the...
hardman & co
Avacta Group Plc
19/07/2016
Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer...

Latest discussion posts More

  • Re: Interims

    The biggest worry with news so imminent, is why the share price has drifted. Always worried "someone knows more than me" I have great hope of great things happening at ...
    21-Mar-2017
    TheDrewster
  • Interims

    scheduled for 03/04/17 probably the undernoted During coming weeks the company is expected to report on the next step in the pre-clinical development process: ...
    20-Mar-2017
    mol42
  • Re: Affimer Technology Hardman Note

    think this is them as noted in Hardman note http://www.immunxperts.com/ mol
    20-Mar-2017
    mol42

Users' HoldingsMore

Users who hold Avacta Group also hold..
LLOYDS GRP.22%
ROCKHOPPER16%
BARCLAYS12%
ROYAL BANK SCOT12%
RENEURON11%

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT